- $58.75m
- $37.87m
- $48.47m
Brief: Gossamer Bio Q2 EPS USD -0.45
Gossamer Bio Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Growth Equity Opportunities 18 Vge Llc Reports 8.2% Stake In Gossamer Bio Inc As Of July 19
U.S. RESEARCH ROUNDUP-Carvana, Heritage-Crystal Clean, Vintage Wine Estates
Brief: Gossamer Bio Announces $212 Mln Private Placement Financing
U.S. RESEARCH ROUNDUP-Allakos, Virtu Financial, Walt Disney
Gossamer Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Gossamer Bio Announces First Quarter 2023 Financial Results
Gossamer Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Gossamer Bio falls on discontinuing development of cancer drug
Brief: Gossamer Bio Inc- U.S. Food And Drug Administration Has Placed A Partial Clinical Hold On All Trials Of GB5121
Gossamer Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Gossamer Bio Inc Reports Quarterly Loss Per Share Of $0.59
Gossamer Bio Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Millennium Management Llc Reports 5.1% Passive Stake In Gossamer Bio Inc As Of December 29 - SEC Filing
U.S. RESEARCH ROUNDUP- Autozone, Nike, Sachem Capital
U.S. STOCKS ON THE MOVE-Moderna, crypto stocks, U.S. banks
U.S. STOCKS ON THE MOVE-Gossamer Bio, Summit Therapeutics, VistaGen
Gossamer Bio hits record low on disappointing heart-lung disorder drug data